Isotopes & Radiation

Framatome and Nuclearelectrica, operator of Romania’s Cernavoda nuclear power plant, announced the signing of a memorandum of understanding to explore the possibility of producing the medical isotope lutetium-177. The cooperative agreement was signed during the World Nuclear Exhibition 2023, held November 28–30 in Paris.

Wisconsin-based fusion technology company SHINE Technologies has signed a long-term supply agreement with Nucleus RadioPharma for the supply of lutetium-177, a radioisotope used in cancer treatment therapies, including those in development for the treatment of neuroendocrine tumors, prostate cancer, and other solid tumors.

BWX Technologies subsidiary BWXT Medical has agreed to provide Fusion Pharmaceuticals with generators to produce actinium-225, a medical isotope used to treat cancer in clinical trials.

The Department of Energy Isotope Program and QSA Global, a Burlington, Mass.–based manufacturer of sealed radioisotope sources, agreed to a joint product development project to initiate domestic production of iridium-192, which is used in industrial gamma ray radiography.

The American Nuclear Society has published the following new standard, which is available for purchase in the ANS Store:

ANSI/ANS-8.21-2023, Use of Fixed Neutron Absorbers in Nuclear Facilities Outside Reactors (revision of ANSI/ANS-8.21-1995; R2019)

A Nuclear Regulatory Commission draft regulatory guide—DG-8061, “Release of Patients Administered Radioactive Material”—proposes guidance on the release of patients after a medical procedure involving the administration of radiopharmaceuticals or the implantation of a sealed source. The guidance is intended to help licensees interpret NRC regulations designed to protect the people—family, friends, caregivers, or members of the general public—who may be in proximity to a patient who is discharged after receiving nuclear medicine treatment.

The International Atomic Energy Agency has carried out the first mission of its Disused Sealed Radioactive Sources Technical Centre peer review service, or DSRS TeC, at the Thailand Institute of Nuclear Technology (TINT) in Bangkok. Held July 18–21, the inaugural mission was supported by funds from the United States.

Crapo

Bipartisan legislation has been reintroduced in Congress to strengthen the Radiation Exposure Compensation Act (RECA), improving compensation for people who were exposed to radiation as a result of working in uranium mines or living near sites of nuclear weapons testing during the Cold War. The legislation was introduced recently in the Senate by Sens. Mike Crapo (R., Idaho) and Ben Ray Luján (D., N.M.) and in the House by Rep. Teresa Leger Fernández (D., N.M.) and Del. James Moylan (R., Guam).

Follow-up bill: Originally introduced by Crapo in 2021, S. 2798 was put forward again to follow up on the success that Crapo, Luján, and Fernández had last year in extending the RECA program into 2024. The reintroduced bill, which added Moylan as a sponsor, would extend the program further to cover more communities with former uranium workers and “downwinders” (people who were exposed to radiation because they lived downwind from weapons testing sites). While the original legislation covered people in parts of Utah, Nevada, and Arizona, the bill will now also cover those who lived in Idaho, Colorado, New Mexico, and Guam.

After more than a decade of global efforts led by the Department of Energy’s National Nuclear Security Administration, all four major medical producers of the radioisotope molybdenum-99 for the U.S. market are now using low-enriched uranium (LEU) in their production processes instead of high-enriched uranium (HEU), the latter of which presents risks of nuclear weapons proliferation.

An Xcel Energy news release issued last week regarding the leak of some 400,000 gallons of tritium-containing water at Minnesota’s Monticello nuclear power plant in 2022 has sparked a flood of news stories over the past few days—in large part because the general public had previously been unaware of the leak. (A low-level beta emitter, tritium is a common byproduct of nuclear reactor operation.)

The Texas Department of State Health Services issued a public notification of a missing radiographic camera in Houston, Texas, on March 11. According to the department, the last known location of the device was 4040 Little York Road, on the northern edge of the city.

In a former farm field just outside the historic town of Janesville in south-central Wisconsin, a large concrete-and-steel building is taking shape. Dubbed the Chrysalis, the building will eventually house eight accelerator-based neutron generators, which start-up company SHINE Technologies will use to produce molybdenum-99. As the precursor to the medical radioisotope technetium-99m, Mo-99 is used in tens of millions of diagnostic procedures every year, primarily as a radioactive tracer.

At the heart of the Chrysalis will be the high-flux neutron generators, being supplied by SHINE’s sister company, Phoenix. The compact accelerators use a deuterium-tritium fusion process to produce neutrons, which in turn induce a subcritical fission reaction in an aqueous low-enriched uranium target (19.75 percent uranium-235) to produce Mo-99.

For the first time since forming in 2020, more than 40 members of a Department of Energy team met in person to evaluate technologies, including exoskeletons and wearable robotic devices, that could be adapted to the cleanup mission of department’s Office of Environmental Management (EM), helping improve the safety and well-being of its workers.

The trouble with tritium is there is no trouble with tritium.

At any level outside the laboratory, either experimental or manufacturing, tritium is harmless. Every year, we routinely release millions of gallons of slightly tritiated water to the ocean, large lakes, and large rivers from almost every commercial nuclear reactor in the world, and have done so for decades, all in accordance with globally accepted nuclear safety standards. And no adverse effects on the environment or humans have ever been seen.

In the summer of 2019, three students from the University of South Carolina–Aiken (USCA) had an idea to digitize the isotope. Wei Zheng, Drake Jones, and Joseph Taylor set out to design an app that would be an interactive one-stop shop for information about any isotope—number of protons and neutrons, whether it is stable or radioactive, its natural abundance on earth, and even its uses. From these ideas, the Interactive Isotopes App began to take shape.

The app’s launch was disrupted by the COVID-19 pandemic; although it was complete after three years of work and development, the creators sat on it. On October 12, the app at long last went live on the ANS website.

The Department of Energy held a groundbreaking ceremony on October 24 for the Stable Isotope Production and Research Center (SIPRC) at Oak Ridge National Laboratory in Tennessee. The center is being built to expand the nation’s capability to enrich stable isotopes for medical, industrial, and research applications.

SHINE Europe, a subsidiary of Wisconsin-based SHINE Technologies, will work with the Netherlands’ University Medical Center Groningen (UMCG) and Delft University of Technology (TU Delft) to produce a variety of terbium isotopes for use in nuclear medicine under a grant proposal approved by the Dutch government on October 17.

Aboveground atomic bomb test at the Nevada Test Site while troops look on. These clouds of material often wafted over to Utah during the 1950s. (Photo: NNSA)

In 1953, the United States detonated above­ground nuclear weapons during tests at the Nevada Test Site. In 2011, the Fukushima Daiichi meltdown occurred in Japan. Both events spread radioactive material over many miles and over population centers. Neither event resulted in any adverse health effects from that radiation.

But the response to the Fukushima event was disastrous because of the irrational and misinformed fear of radiation. That fear—not radiation—killed at least 1,600 people and destroyed the lives of at least another 200,000. That fear seriously harmed the entire economy of Japan, stopped cold the fishing industry and other agriculture in that area, and, overnight, reversed the country’s progress in addressing climate change.

The U.S. tests spread two to three times more radiation than did the events of Fukushima over the people of Utah, particularly the town of St. George. Like with Fukushima, no one was hurt, there was never any increase in cancer rates, and no one died as a result. But in Utah, the economy and people’s lives were unaffected. Why was there such a different result?

SHINE Technologies, the Janesville, Wis.–based producer of medical radioisotopes, announced that it has submitted a drug master file (DMF) with the U.S. Food and Drug Administration for non-carrier-added (n.c.a.) lutetium-177 chloride, a radiopharmaceutical used for the treatment of cancer.

A new report from the National Academies of Sciences, Engineering, and Medicine (NASEM) estimates that $100 million annually will be required for the next 15 years to develop a coordinated research program led by the Department of Energy and the National Institutes of Health to study how low doses of radiation affect disease risk. The recommended research would investigate causal links to specific health conditions and better define the impacts of radiation doses, dose rates, types of radiation, and exposure duration.